MMP9 and Myocardial fibrosis: The findings indicated that reynoutrin inhibited MMP2 and MMP9 expressions, as well as NF-κB transcription activity by targeting S100A1, thereby alleviating myocardial inflammation and oxidative stress, reducing infarct size and cardiomyocytes apoptosis, reducing myocardial fibrosis, and show improvements in heart failure caused by ischemia.